Phase 1 Leukaemia Trial, Recruiting NCT06737523 Sponsor: The First Affiliated Hospital of Xiamen University Condition: Leukaemia
Back to Leukaemia

Phase 1 Leukaemia Trial, Recruiting

NCT06737523
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with acute myeloid leukemia (AML) confirmed by laboratory testing, where the disease has either not responded to at least one prior treatment, or has come back after a period of remission — this also includes AML that developed from certain other blood or bone marrow conditions
  • Adults aged 18 or older, of any sex, with a life expectancy of more than 3 months
  • People whose kidneys are functioning well enough, based on a specific blood test measuring kidney filtering ability (confirm with trial site for exact threshold)
  • People whose liver function tests are within an acceptable range, unless any abnormality is caused by the leukemia itself (confirm with trial site for exact values)
  • People who are reasonably physically functional — rated at a level of 2 or below on a standard medical activity scale, meaning capable of self-care even if not able to do heavy physical work
  • People who are not pregnant, or who are using reliable contraception during the treatment period
  • People who are able to understand the study information and give their consent to participate voluntarily

Who may not be able to join:

  • People whose AML is specifically the type called acute promyelocytic leukemia (APL)
  • People whose leukemia has spread to the central nervous system (brain and spinal cord) and is currently active
  • People with certain heart conditions, including a specific type of irregular heart rhythm measurement on an ECG, irregular heartbeats, a history of heart attack or heart failure within the past year, or coronary heart disease currently requiring medication
  • People with a serious active infection that is not under control
  • People who have had another non-blood cancer within the past 2 years
  • People with a mental health condition that would make it difficult to take part in the study
  • People who have previously received a solid organ transplant (a prior stem cell transplant may be acceptable, but not if the person is still experiencing graft-versus-host disease or is still on related medications)
  • People who, in the opinion of the trial doctors, have any other condition that makes participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bing Xu, The First Aiffiliated hosptical of xiamen University

Phone: 18750918842

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
The First Affiliated Hospital of Xiamen University
Registry
ClinicalTrials.gov
Start date
15 March 2025
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Complete remission rate (CR); Complete Remission with Incomplete Count Recovery (CRi); Partial remission rate (PR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov